UnitedHealthcare Tocilizumab (Actemra) prior authorization requirements (2026)
What UnitedHealthcare generally requires to approve Tocilizumab (Actemra) (CPT J3262), for UnitedHealthcare Community Plan (Medicaid); a parallel Commercial policy applies to commercial members plans. Yes. UnitedHealthcare generally requires prior authorization for Tocilizumab (Actemra) (CPT J3262).
Medical-necessity criteria UnitedHealthcare generally applies
Medical benefit drug policy; Tofidence (tocilizumab-bavi) and Tyenne (tocilizumab-aazg) are preferred. RHEUMATOID ARTHRITIS (prescribed by/with a rheumatologist): moderately-to-severely active RA AND one of: failure/intolerance to a 3-month trial of a non-biologic DMARD (methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses unless contraindicated, OR prior RA-approved targeted immunomodulator. GIANT CELL ARTERITIS: diagnosis of GCA; not combined with another targeted immunomodulator (sarilumab, abatacept, upadacitinib). Dosed per FDA labeling; initial authorization up to 12 months; continuation requires documented positive clinical response.
Diagnoses that commonly support medical necessity
ICD-10-CM diagnoses frequently associated with medical necessity for Tocilizumab (Actemra). Confirm the covered diagnosis list against the current UnitedHealthcare policy.
Commonly required documentation
- Diagnosis
- conventional-DMARD or prior-targeted-immunomodulator history
- FDA-compliant dosing.
Situations to verify before submitting
UnitedHealthcare may not cover Tocilizumab (Actemra) in these situations. Verify against the current policy rather than assuming a denial:
- Not covered in combination with another systemic targeted immunomodulator for the same indication
How to submit
- Method: UnitedHealthcare provider portal (medical benefit drug review)
- Portal: UnitedHealthcare Provider Portal
Source
Source: UHC Community Plan Medical Benefit Drug Policy CS2026D0043AJ Tocilizumab (eff 2026-04-01). NOTE: Medicaid line of business; UHC Commercial has a parallel policy with similar structure - verify LOB before a commercial appeal. Code J3262. Last verified 2026-06-17.
Frequently asked questions
Does UnitedHealthcare require prior authorization for Tocilizumab (Actemra)?
Yes. UnitedHealthcare generally requires prior authorization for Tocilizumab (Actemra) (CPT J3262).
What does UnitedHealthcare require to approve Tocilizumab (Actemra)?
Medical benefit drug policy; Tofidence (tocilizumab-bavi) and Tyenne (tocilizumab-aazg) are preferred. RHEUMATOID ARTHRITIS (prescribed by/with a rheumatologist): moderately-to-severely active RA AND one of: failure/intolerance to a 3-month trial of a non-biologic DMARD (methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses unless contraindicated, OR prior RA-a… Always confirm against the current UnitedHealthcare policy.
How long does a UnitedHealthcare prior authorization take?
Turnaround varies by plan and submission method. Check the UnitedHealthcare portal for current timeframes.
Submitting Tocilizumab (Actemra) to UnitedHealthcare?
Praxigen checks your clinical note against these criteria before you submit and drafts a policy-cited appeal if it is denied. You review and submit; nothing is sent automatically.